Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Post by Hoptimiston Apr 13, 2019 2:47pm
190 Views
Post# 29623164

Heuro Clinics

Heuro ClinicsWell...I'm glad I only bet my tractor and not the entire farm on Helius.  

So much for Phil being "extremely confident" about FDA approval. I'm still holding all of my shares, with the hope that European approval and testimonials from the Vancouver and Montreal Heuro clinics might help move the SP to recoup some of my substantial paper loss.

As the Heuro physio programs are shown to last 14 weeks, i would expect that by July/August, word might be spreading that the PonS/physio treatment is significanty helping TBI patients (if it indeed does).

In the meantime, maybe my investment in Profound Medical might begin to pay off, especially given the 96% success rate of their prostate cancer treatment trial announced a week ago. 

Along with everyone else, I'm now acutely interested to hear Helius management's Plan B.

Hoptimist
Bullboard Posts